We also elected to continue moderately aggressive fluid resuscitation despite an elevated NT‐proBNP and the risk of cardiac complications following COVID‐19, as the benefit of preventing TLS was deemed greater than the potential risks of fluid overload. Here, NPPB is linked to COVID-19.